Synonyms: compound 68 [WO2010002845A2] | HMPL-813 | HMPL813
Compound class:
Synthetic organic
Comment: Epitinib (HMPL-813) is a selective EGFR tyrosine kinase inhibitor that is under investigation for potential to treat solid tumours in China. Epitinib appears to be a 'pseudo' INN. As of July 2021 there had been no submission to the WHO for the INN. The chemical structure is claimed in patent WO2010002845A2 [1].
|
|
References |
1. Zhang W, Su W-G, Yang H, Cui Y, Ren Y, Yan X. (2010)
Quinazoline derivatives. Patent number: WO2010002845A2. Assignee: Hutchison Medipharma. Priority date: 30/06/2008. Publication date: 13/07/2021. |